# Fremanezumab, Migraine and Sleep

> **NCT04693533** · PHASE4 · TERMINATED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 22 (actual)

## Conditions studied

- Migraine Disorders
- Sleep Disorder

## Interventions

- **DRUG:** Fremanezumab Prefilled Syringe [Ajovy]

## Key facts

- **NCT ID:** NCT04693533
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-29
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** poor enrollment
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04693533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04693533, "Fremanezumab, Migraine and Sleep". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04693533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*